Introduction {#s1}
============

DNA-binding transcription factors (TFs) typically recognize short 6--12 base-pair motifs, which exist at a high frequency in mammalian genomes ([@bib44]; [@bib37]). While chromatin restricts the accessibility of these sequences, TFs nonetheless occupy thousands of genomic sites in any given cell type ([@bib37]). As examples, MyoD has been detected at ∼39,000 sites in primary myotubes and Pax5 at ∼20,000 sites in B cell progenitors ([@bib9]; [@bib33]). Furthermore, transcriptional cofactors (coactivators and corepressors) are also known to occupy the mammalian genome in a generalized manner ([@bib31]). Thus, strong support exists for a model in mammalian cells in which transcriptional control is performed by regulators that exert broad, yet highly coordinated effects on gene expression ([@bib44]; [@bib37]). This is in stark contrast to prokaryotic species, in which TFs can occupy as few as one or two sites in an entire genome to implement precise transcriptional responses ([@bib25]; [@bib44]). Whether such a degree of gene-specificity exists among mammalian transcriptional regulators is currently unknown.

TRIM33, also known as TIF1γ, belongs to the tripartite motif (TRIM)-containing protein family of E3 ubiquitin ligases ([@bib40]; [@bib19]; [@bib21]). TRIM33 and its homologs TRIM24 and TRIM28 belong to a subfamily of ubiquitously expressed TRIM proteins that contain a tandem plant homeodomain (PHD) and bromodomain module and function as transcriptional cofactors ([@bib40]). One role of TRIM33 is in the TGFβ signaling pathway, which occurs through regulation of SMAD4 mono-ubiquitination and/or by functioning as a cofactor for the TFs SMAD2 and SMAD3 ([@bib14], [@bib13]; [@bib20]; [@bib1]). TRIM33 is also known to interact with the TF SCL/TAL1 to promote transcription elongation of erythroid-specific genes, which may occur through the recruitment of FACT and P-TEFb complexes ([@bib4], [@bib5]). However, another study suggests that TRIM33 can form repressive complexes with SCL to block transcriptional activation ([@bib23]). The PHD-bromodomain module of TRIM33 interacts with covalently modified histone tails, which can further stabilize TRIM33 chromatin occupancy and stimulate its E3 ligase activity ([@bib39]; [@bib1]; [@bib45]). While several studies have linked TRIM33 to transcriptional control, a genomewide assessment of TRIM33 occupancy has yet to be performed to define the scope of its regulatory function.

Results {#s2}
=======

RNAi screen identifies TRIM33 as a lineage dependency in cancers of B cell origin {#s2-1}
---------------------------------------------------------------------------------

In an ongoing effort to identify roles for chromatin regulators as cancer dependencies, we carried out a negative selection RNAi screen in a cell line derived from a mouse model of high risk B cell acute lymphoblastic leukemia (B-ALL), initiated by introducing the BCR-ABL oncogene into *Arf*-null bone marrow cells ([@bib42]). 1,126 shRNAs targeting 259 chromatin regulators were assessed individually for effects on the viability of B-ALL cells in culture, which led to the identification of 16 dependencies after applying stringent scoring criteria ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The majority of these factors had been identified in a prior screen that evaluated the requirement of chromatin regulators in MLL-AF9/Nras^G12D^ acute myeloid leukemia (AML) ([@bib47]), however TRIM33 was identified here as a unique requirement in B-ALL. The six TRIM33 shRNAs used in the screen exhibited a close correlation between knockdown efficiency and loss of B-ALL viability, suggesting on-target effects ([Figure 1A,B](#fig1){ref-type="fig"}). Furthermore, a v-Abl transformed B cell progenitor line, 38B9 ([@bib2]), and several human B cell cancer lines were also sensitive to TRIM33 knockdown ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In contrast, TRIM33 knockdown led to negligible effects on the viability of MLL-AF9/Nras^G12D^ AML and Notch-mutant T-cell acute lymphoblastic leukemia (T-ALL) ([Figure 1D,E](#fig1){ref-type="fig"}). Upon knockdown of TRIM33, B-ALL cells underwent apoptosis, as shown by Annexin V/DAPI staining ([Figure 1F](#fig1){ref-type="fig"}). Taken together, these observations suggest that TRIM33 is essential for the survival of neoplastic B cells.10.7554/eLife.06377.003Figure 1.RNAi screen identifies TRIM33 as a lineage dependency in cancers of B cell origin.(**A**) Negative selection shRNA screen targeting chromatin regulators in murine B cell acute lymphoblastic leukemia (B-ALL). shRNAs are rank ordered by the fold-change in GFP positivity over 10 days in culture, which represents a competition-based assay in which loss of GFP positivity reflects shRNA-postive cells becoming outcompeted by shRNA-negative cells. (**B**--**E**) Competition-based assays and Western blotting to evaluate the effect of TRIM33 shRNAs on B-ALL, 38B9, acute myeloid leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL) cells. GFP percentages are normalized to day 2 measurements. Results are the average of three biological replicates. (**F**) Annexin V/DAPI staining following transduction of B-ALL cells with the indicated MLS shRNAs on day 3 post-transduction. Representative experiment of three biological replicates is shown. (**G**) shRNA transgenic mouse strategy. TRE: tet(doxycycline) response element; rtTA-M2: reverse tet transactivator M2 variant (tet-on). (**H**) Western blotting performed of indicated tissue lysates prepared from mice treated with dox for 4 weeks. Representative experiment of three biological replicates is shown. (**I**--**J**) Flow cytometry analysis using the indicated antibody stainings of whole bone marrow or spleen. B220 and Cd19: B lymphoid, Ter119: erythroid, Gr1 and Mac1: myeloid, Cd3: T lymphoid. Gating was performed on GFP^+^/shRNA^+^ cells prior to quantifying marker positivity. The GFP^+^ percentage in bone marrow was ∼75% and in the spleen was ∼15%. Mice were administered dox for 1 week or 4 weeks, with both timepoints giving similar results. Results shown are the average 4 or 5 mice. All error bars in this figure represent S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.003](10.7554/eLife.06377.003)10.7554/eLife.06377.004Figure 1---figure supplement 1.Hits identified in the shRNA screen and validation experiments in human cell lines.(**A**) B-ALL chromatin regulator dependencies identified in the shRNA screen. 68 shRNAs in the primary screen were depleted \>10-fold over 10 days in culture. By setting a criteria of having at least 2 independent shRNAs targeting the same gene exhibiting \>10-fold GFP depletion, we identified 16 dependencies, indicated here. An Rpa3 shRNA was included as a positive control. A Renilla luciferase shRNA was included as a negative control. Each horizontal bar represents an independent shRNA, except for Rpa3 and Renilla controls which are independent experiments with the same shRNA. Fold-depletion was capped at 50-fold for visualization purposes. Results were compared with prior screening results and validation experiments performed in MLL-AF9/Nras^G12D^ AML to identify TRIM33 was a unique dependency in B-ALL ([@bib47]). (**B**--**E**) Competition-based proliferation assays using the indicated TRIM33 or Ren shRNA expressing MLS-E vectors, which were transduced into the indicated human cell lines. All experiments shown represent the average of three biological replicates. Error bars represent S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.004](10.7554/eLife.06377.004)10.7554/eLife.06377.005Figure 1---figure supplement 2.Additional analysis of TRIM33 shRNA transgenic mice.(**A**) Immunohistochemical analysis of anti-TRIM33 antibody staining shTRIM33 or shRen adult mice (heterozygous) following 30 days of doxycycline administration. All mice were homozygous for the ROSA26-rtTA-M2 transgene. Counterstaining was performed with Hematoxylin. (**B**) Hematoxylin and Eosin staining of indicated tissues. (**C** and **D**) Analysis of the reversibility of the B cell phenotype in TRIM33 knockdown mice as compared to Renilla shRNA control. Mice were treated for 7 days ON dox or were treated with 7 days ON dox followed by 21 days OFF dox, as indicated. GFP gating was not performed for this analysis, since in the OFF dox condition the GFP reporter is extinguished. n = 4 or 5. (**E**) Animal weight measurements following dox administration. Error bars represent S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.005](10.7554/eLife.06377.005)

To compare the TRIM33 requirement in B-ALL with its role in normal tissues, we derived transgenic mice in which a TRIM33 shRNA was expressed from a doxycycline (dox)-regulated promoter ([Figure 1G](#fig1){ref-type="fig"}) ([@bib28]). When crossed with mice that express rtTA-M2 from the ROSA26 promoter, animals exhibited dox-dependent suppression of TRIM33 in multiple tissues ([Figure 1G,H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Flow cytometry analysis of the bone marrow and spleen following 1 or 4 weeks of dox administration revealed a selective loss of CD19^+^ and B220^+^ B lymphoid cells in TRIM33-deficient animals, while erythroid, myeloid, and T lymphoid populations remained intact or even increased in relative abundance ([Figures 1I,J](#fig1){ref-type="fig"}). Taking advantage of the reversibility of the dox-regulated shRNA system, we found that B cell production recovered fully in TRIM33-deficient mice upon restoring TRIM33 expression ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Notably, TRIM33 knockdown led to negligible effects on the histological appearance of colon, liver, thymus, and pancreatic tissues and led to no significant changes in animal weight ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Collectively, these findings suggest that B lymphoid cells are uniquely sensitive to TRIM33 inhibition, thus implicating TRIM33 as a lineage dependency in cancers of B cell origin. These results are in agreement with the prior characterization of *Trim33*^*−/−*^ mice, which were found to exhibit a B lymphocyte deficiency and an expansion of myeloid cells ([@bib3]; [@bib23]; [@bib5]).

TRIM33 preferentially associates with two lineage-specific enhancers in B lymphoblastic leukemia cells {#s2-2}
------------------------------------------------------------------------------------------------------

We next evaluated the mechanism underlying the essential TRIM33 function in B cell neoplasms. To this end, we performed RNA-seq analysis in B-ALL cells following 3 or 4 days of TRIM33 knockdown. This analysis revealed a distribution of gene expression changes, however, we noted that *Bim* and *Atp1b3* were the two most upregulated genes upon TRIM33 depletion ([Figure 2A](#fig2){ref-type="fig"}). To evaluate whether any of these mRNA changes were due to direct regulation, we performed ChIP-seq analysis in B-ALL cells to evaluate the genomic localization of TRIM33 and various histone modifications that annotate active promoter and enhancer regions. Remarkably, the two strongest sites of TRIM33 enrichment in B-ALL were located 117 kb upstream of *Bim* (in an intron of a non-expressed gene *Acoxl*) and at a site 35 kb upstream of *Atp1b* ([Figure 2B--D](#fig2){ref-type="fig"}). The other gene expression changes incurred upon TRIM33 knockdown did not correlate with its genomic occupancy (data not shown), suggesting they might be an indirect effect of B-ALL cells initiating an apoptotic response. The TRIM33-occupied regions upstream of *Bim* and *Atp1b3* were enriched for H3K27 acetylation but not for H3K4 tri-methylation, suggesting that these elements are active enhancers ([@bib30]) ([Figure 2C,D](#fig2){ref-type="fig"}). We also observed TRIM33 occupancy at these same two regions in 38B9, AML, and in whole spleen, but not in T-ALL ([Figure 2---figure supplements 1, 2](#fig2s1 fig2s2){ref-type="fig"}). A striking attribute of the genomewide pattern of TRIM33 occupancy was its strong bias for a small number of locations, with lower levels of enrichment at other sites across the genome ([Figure 2E,F](#fig2){ref-type="fig"}, and [Figure 2---figure supplements 3, 4](#fig2s3 fig2s4){ref-type="fig"}). This analysis suggests that TRIM33 is concentrated at a small number of sites in the B-ALL genome, with two of these regions correlating with a repressive effect on the expression of nearby *Atp1b3* and *Bim* genes.10.7554/eLife.06377.006Figure 2.TRIM33 preferentially associates with two lineage-specific enhancers in B lymphoblastic leukemia cells.(**A**) RNA-seq analysis of B-ALL cells transduced with shTRIM33.1271. shRNA^+^/GFP^+^ cells were sorted on day 3 or 4 post-infection. Plotted is the average fold-change in mRNA level of two independent biological replicates. (**B**) Ranking of TRIM33 occupied sites based on average tag counts obtained from B-ALL ChIP-seq analysis. The 31 regions shown represent the significant reproducible peaks identified in two independent biological replicates. (**C**--**F**) B-ALL ChIP-seq occupancy profiles using the indicated antibodies. The y-axis reflects the number of cumulative tag counts in the vicinity of each region. Validated transcript models from the mm9 genome assembly are depicted below.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.006](10.7554/eLife.06377.006)10.7554/eLife.06377.007Figure 2---figure supplement 1.(**A**--**B**) TRIM33 ChIP-seq occupancy profiles at the Bim locus (**A**) and the Atp1b3 locus (**B**) in the indicated cell types.Validated transcript models from the mm9 genome assembly are depicted below.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.007](10.7554/eLife.06377.007)10.7554/eLife.06377.008Figure 2---figure supplement 2.Trim33 ChIP-qPCR analysis in various cell lines.(**A**--**B**) ChIP-qPCR validation of TRIM33 occupancy at the Bim or Atp1b3 loci in the indicated cell lines. qPCR amplicons were designed at the indicated locations of the *Bim* or *Atp1b3* loci. Labels refer to kilobase distance relative to *Bim* or *Atp1b3* transcriptional start site (TSS). Plotted is the average of three biological replicates. Error bars denote S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.008](10.7554/eLife.06377.008)10.7554/eLife.06377.009Figure 2---figure supplement 3.(**A**--**D**) Comparison of two independent TRIM33 ChIP-seq biological replicates in B-ALL.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.009](10.7554/eLife.06377.009)10.7554/eLife.06377.010Figure 2---figure supplement 4.TRIM33 ChIP-seq analysis in 38B9, AML, and T-ALL.(**A**) Ranking of TRIM33 occupied sites based on average tag counts obtained from ChIP-seq analysis in the indicated cell lines. The regions shown represent the reproducible peaks identified in each of two independent biological replicates. The Bim-117 and Atp1b3-35 regions are as indicated in 38B9 and AML. In T-ALL we did not identify these regions as robust peaks and instead we labeled the top two outlier TRIM33 peaks in this cell type. (**B**) MEME-based motif analysis at 400 bp windows centered on TRIM33 occupied peaks shown in **A**. The distribution of motifs in this window is indicated on the right.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.010](10.7554/eLife.06377.010)

TRIM33 preferentially associates with enhancers harboring an exceptional density of the PU.1 TF {#s2-3}
-----------------------------------------------------------------------------------------------

We next pursued the mechanism underlying the profound accumulation of TRIM33 at the *Bim* --117 and *Atp1b3* --35 regions in B-ALL. Using the FIMO motif analysis tool ([@bib18]), we found that both of these regions possessed a high density of sequence motifs recognized by PU.1 (17 instances at *Bim* --117 and 14 instances at *Atp1b3* --35), which is an essential hematopoietic TF expressed in B lymphoid and myeloid lineages ([@bib34]). In contrast, we observed a much lower density of motifs for other TFs involved in B cell specific transcriptional regulation (E2A, EBF1, or PAX5) ([Figure 3A,B](#fig3){ref-type="fig"}). Since TRIM33 has been shown previously to interact with PU.1 ([@bib23]), we investigated whether PU.1 promotes TRIM33 recruitment to these regions. ChIP-seq analysis of PU.1 in B-ALL confirmed its association with *Bim* --117 and *Atp1b3* --35, as well as with more than 2600 other genomic sites ([Figure 2C,D](#fig2){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Remarkably, *Bim* --117 and *Atp1b3* --35 regions are outliers when compared to other PU.1-occupied sites with regard to the overall density of PU.1 recognition motifs and the overall level of PU.1 enrichment ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The level of the active enhancer chromatin mark, H3K27ac, is not skewed in a similar manner towards these two locations, indicating that these regions are not super-enhancers that exhibit high levels of all regulators ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) ([@bib22]). Using ChIP-qPCR, we also confirmed PU.1 occupancy at these two regions in 38B9 and AML cells, but not in T-ALL ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).10.7554/eLife.06377.011Figure 3.TRIM33 is recruited by PU.1 to select enhancers and antagonizes PU.1 function to promote B-ALL survival.(**A**) Motif analysis using the FIMO/MEME algorithm. The table indicates the number of motif matches in each sequence interval. (**B**) Schematic diagram of PU.1 motif (MA0080.3) locations across the indicated *cis* elements. (**C**) Analysis of PU.1 motifs (MA0080.3) counts at all of the 2682 PU.1 peaks identified by ChIP-seq. (**D**--**I**) ChIP-qPCR analysis at the indicated locations of the *Bim* locus in B-ALL. Labels refer to the kilobase distance relative to the *Bim* TSS. For TRIM33 knockdown experiments (**G**--**I**), both shRen and shTRIM33 were introduced into B-ALL cells harboring a Bim shRNA. Plotted is the average of three biological replicates. (**J**) Competition-based assay evaluating effect of a PU.1 shRNA on the sensitivity of B-ALL cells to TRIM33 knockdown. shRen or shPU1 linked to GFP were introduced first into B-ALL cells and then were subsequently transduced with shTRIM33 or shRen linked to mCherry. The GFP/mCherry double positive population was measured over time. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. All error bars in this figure represent S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.011](10.7554/eLife.06377.011)10.7554/eLife.06377.012Figure 3---figure supplement 1.(**A**--**B**) Ranked ordering of PU.1 and H3K27 acetylation peaks identified using ChIP-seq analysis in B-ALL.Peaks were ranked based on sequence tag counts. Positions of *Bim*-117 and *Atp1b3*-35 are indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.012](10.7554/eLife.06377.012)10.7554/eLife.06377.013Figure 3---figure supplement 2.(**A**--**B**) PU.1 ChIP-qPCR analysis at the indicated locations of *Bim* (**A**) and *Atp1b3* (**B**) loci in 38B9, AML, and T-ALL.Labels refer to kilobase distance relative to TSS. Plotted is the average of three biological replicates. Error bars denote S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.013](10.7554/eLife.06377.013)10.7554/eLife.06377.014Figure 3---figure supplement 3.Additional PU.1 knockdown experiments.(**A**) Validation of Pu.1 shRNA by Western blotting. Experiment was performed in MLP-GFP transduced B-ALL cells following puromycin selection. (**B**--**C**) Effect of PU.1 knockdown on TRIM33 occupancy at *Atp1b3*. ChIP-qPCR analysis at the indicated locations of the *Atp1b3* locus in B-ALL. Labels refer to kilobase distance relative to *Atp1b3* TSS. Plotted is the average of three biological replicates. Error bars denote S.E.M. (**D**) Effect of PU.1 knockdown on Bim expression. RNA was prepared from B-ALL cells transduced with indicated shRNAs and used for reverse transcription. Plotted is the average of three biological replicates. Results were normalized to *Gapdh*.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.014](10.7554/eLife.06377.014)10.7554/eLife.06377.015Figure 3---figure supplement 4.Competition-based assay evaluating effect of a PU.1 shRNA on the sensitivity of 38B9 cells to TRIM33 knockdown.shRen or shPU1 linked to GFP were introduced first into B-ALL cells and then were subsequently transduced with shTRIM33 or shRen. The GFP/mCherry double positive population was measured over time. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. All error bars in this figure represent S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.015](10.7554/eLife.06377.015)

These findings raised the possibility that an exceptional density of PU.1 at these two sites might serve as the trigger for TRIM33 recruitment. To evaluate this, we used shRNAs to derive PU.1-deficient B-ALL cells, which displayed normal proliferation and viability ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}, data not shown). We found that PU.1 knockdown led to a significant loss of TRIM33 occupancy at *Bim* and *Atp1b3* in proportion to the loss of PU.1 ([Figure 3D,E](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). PU.1-deficient B-ALL cells also harbored reduced H3K27ac at *Bim* --117 and reduced *Bim* mRNA levels, suggesting that PU.1 is responsible for maintaining this enhancer in an active state while, paradoxically, also facilitating TRIM33 recruitment ([Figure 3F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Collectively, these results suggest that a high density of PU.1 underlies the skewed distribution of TRIM33 genomic occupancy observed in B-ALL.

TRIM33 antagonizes PU.1 function to promote B-ALL cell survival {#s2-4}
---------------------------------------------------------------

Since PU.1 and TRIM33 appear to have opposing effects on *Bim* expression ([Figure 2A](#fig2){ref-type="fig"} and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), we next evaluated how TRIM33 regulates the function of PU.1 at their co-occupied sites. Interestingly, knockdown of TRIM33 led to an increase in PU.1 occupancy and H3K27 acetylation at *Bim* --117, suggesting that TRIM33 antagonizes PU.1 binding to DNA and suppresses enhancer activity, consistent with prior findings ([@bib23]) ([Figure 3G--I](#fig3){ref-type="fig"}). This result is significant, since *Bim* --117 is already heavily enriched for PU.1 in B-ALL cells, but PU.1 occupancy becomes even greater when TRIM33 is suppressed. Consistent with the functional importance of PU.1 antagonism by TRIM33, we found that knockdown of PU.1 resulted in a reduced sensitivity of B-ALL and 38B9 cells to the lethal effects of TRIM33 knockdown ([Figure 3J](#fig3){ref-type="fig"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Collectively, these observations suggest that TRIM33 antagonizes PU.1-dependent enhancer activation as part of its essential function in B lymphoblastic leukemia.

TRIM33 occupancy at a single Bim enhancer accounts for its essential function in B-ALL {#s2-5}
--------------------------------------------------------------------------------------

*Bim* encodes a BH3-only domain protein with a well-established pro-apoptotic function ([@bib43]). Therefore, we considered whether repression of *Bim* is the essential role of TRIM33 in B-ALL. For this purpose we suppressed *Bim* using shRNAs and evaluated how this influenced the sensitivity of cells to TRIM33 knockdown ([Figure 4A,B](#fig4){ref-type="fig"}). Notably, *Bim*-deficient B-ALL cells were completely resistant to the apoptotic effects of TRIM33 shRNAs, indicating that *Bim* is the critical downstream repression target of TRIM33 to maintain cell viability ([Figure 4B](#fig4){ref-type="fig"}). In contrast, *Atp1b3* knockdown did not alter the sensitivity of B-ALL to TRIM33 suppression (data not shown). To further evaluate whether the essential function of TRIM33 is due to its occupancy at the −117 region, we employed CRISPR-Cas9 to delete this element ([@bib11]; [@bib24]) ([Figure 4C,D](#fig4){ref-type="fig"}). Similar to the effects observed upon *Bim* knockdown, three independent B-ALL clones harboring a homozygous deletion of the −117 element did not require TRIM33 for viability ([Figure 4E](#fig4){ref-type="fig"}). *Bim* knockdown and the deletion of the *Bim* --117 region also rendered 38B9 cells resistant to the lethal effects of TRIM33 suppression ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). This indicates that a single genomic binding site at the *Bim* locus accounts for the entire TRIM33 requirement in preventing B-ALL apoptosis.10.7554/eLife.06377.016Figure 4.TRIM33 occupancy at a single Bim enhancer accounts for its essential function in B-ALL.(**A**) Western blot performed on extracts prepared from B-ALL following transduction with the indicated shRNAs. Labeled are two of the known Bim isoforms. TRIM33.3905 shRNA was used. (**B**) Competition-based assay evaluating the effect of Bim knockdown on the sensitivity of B-ALL cells to TRIM33 knockdown. shRen or shBim linked to GFP were introduced first into B-ALL cells and then were subsequently transduced with shTRIM33 or shRen linked to mCherry. The GFP/mCherry double positive population was measured over time. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. (**C**) Experimental design for generating a homozygous deletion of the *Bim* --117 region using CRISPR-Cas9. sgRNAs were designed to cut at locations flanking the TRIM33 binding site to delete the intervening 1.4 kb. Location of PCR primers used for genotyping are indicated. (**D**) Genotyping PCR to track the CRISPR-based deletion. Parental refers to Cas9^+^ B-ALL cells. +sgRNAs refers to Cas9^+^ B-ALL cells co-transduced with two sgRNAs targeting the *Bim* --117 element linked to mCherry reporters. Three clonal lines were derived by limiting dilution. (**E**) Competition-based assay evaluating the effect of the *Bim* --117 deletion on the sensitivity to TRIM33 knockdown. B-ALL cells were transduced with indicated shRNAs linked to GFP reporters. TRIM33.3905 shRNA was used. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. All error bars in this figure represent S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.016](10.7554/eLife.06377.016)10.7554/eLife.06377.017Figure 4---figure supplement 1.Additional experiments evaluating the role of Bim in 38B9 cells.(**A**) Competition-based assay evaluating the effect of Bim knockdown on the sensitivity of 38B9 cells to TRIM33 knockdown. shRen or shBim linked to GFP were introduced first into 38B9 cells and then were subsequently transduced with shTRIM33 or shRen linked to mCherry. The GFP/mCherry double positive population was measured over time. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. (**B**) Genotyping PCR to track the CRISPR-based deletion, as described in [Figure 4D](#fig4){ref-type="fig"}. Parental refers to Cas9^+^ 38B9 cells. +sgRNAs refers to Cas9^+^ 38B9 cells co-transduced with two sgRNAs targeting the *Bim*-117 element linked to mCherry reporters. Three clonal lines were derived by limiting dilution. (**C**) Competition-based assay evaluating the effect of the *Bim*-117 deletion on the sensitivity to TRIM33 knockdown. 38B9 cells were transduced with indicated shRNAs linked to GFP reporters. TRIM33.3905 shRNA was used. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. All error bars in this figure represent S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.017](10.7554/eLife.06377.017)10.7554/eLife.06377.018Figure 4---figure supplement 2.Additional experiments evaluating the role of TRIM33 in AML and T-ALL.(**A**) RT-qPCR analysis of Bim mRNA levels following TRIM33 shRNA transduction into the indicated cell lines. Plotted is the average of three biological replicates. Results were normalized to *Gapdh*. (**B**) ChIP-seq occupancy profile of H3K27 acetylation in the indicated cell lines. Arrows indicate the location of the *Bim*-117 and -66 regions (see text). The H3K27ac ChIP-seq data from AML was derived from ([@bib36]).**DOI:** [http://dx.doi.org/10.7554/eLife.06377.018](10.7554/eLife.06377.018)

While both B lymphoid and myeloid leukemia cells harbor PU.1 and TRIM33 at the *Bim* --117 region, it is important to note that knockdown of TRIM33 in AML does not result in apoptosis or *Bim* upregulation ([Figure 1D](#fig1){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). ChIP-seq analysis of H3K27ac revealed that AML cells possess a large cluster of active enhancers located 66 kb upstream of *Bim*, which is not observed in B-ALL ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Importantly, the level of H3K27ac at this AML-specific enhancer cluster is much greater than that observed at the −117 region. This leads us to speculate that the AML-specific enhancers at the −66 kb region might be the dominant regulatory elements at the *Bim* locus in this cell type. The overall strength of these enhancers in AML may diminish the functional significance of the −117 element, thereby rendering TRIM33 dispensable for AML survival.

Discussion {#s3}
==========

Here we provide evidence that TRIM33 prevents apoptosis in murine B-ALL cells by blocking enhancer-mediated *Bim* activation. The role of TRIM33 as a negative regulator of enhancer activity is reminiscent of LSD1, a histone demethylase that has been shown previously to suppress active enhancers during embryonic stem (ES) cell differentiation ([@bib41]). However, a key distinction we make here is that LSD1 suppresses thousands of enhancers in ES cells, while TRIM33 preferentially accumulates at a small number of regulatory elements in the B-ALL genome. We trace this unusual enhancer selectivity of TRIM33 in B-ALL to the density of PU.1, a TF which has been shown previously to associate with TRIM33 ([@bib23]). This binding interaction is likely to be cooperative on motif-rich DNA elements, which would account for the biased accumulation of TRIM33 at enhancers harboring an exceptional PU.1 density. Our ChIP-seq analysis of TRIM33 in myeloid, B lymphoid, and T lymphoid leukemias suggests that other TFs are also likely to recruit TRIM33, such as TCF3/E2A ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). To our knowledge, TRIM33 is the first example of a mammalian transcriptional regulator that performs an essential function through a single genomic binding site.

The selective occupancy of TRIM33 within the active enhancer landscape may account for the minimal phenotypes observed in TRIM33-deficient mice. This is in contrast to the effects of suppressing BRD4, a more general cofactor that is essential for the maintenance of many cancer types and for the homeostasis of several normal tissues ([@bib7]; [@bib35]). Remarkably, it is the localization of TRIM33 to one lineage-specific enhancer upstream of *Bim* that renders B-ALL cells hypersensitive to loss of TRIM33. The similar sensitivity of normal and transformed B cells to TRIM33 inhibition implies that the regulatory mechanisms defined here in B cell leukemia are likely to have evolved to control normal B cell development. Interestingly, *Bim* is upregulated as a means to eliminate auto-reactive B cells and to prevent autoimmune disease, suggesting a rationale for precise modulation of enhancer activity at the *Bim* locus by TRIM33 to regulate adaptive immunity ([@bib8]; [@bib16]).

In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease ([@bib10]; [@bib15]). Hence, our findings also implicate TRIM33 as a promising therapeutic target, since one of the major phenotypic abnormalities in mice experiencing systemic TRIM33 inhibition is a selective and reversible B lymphocyte deficiency. Targeting of TRIM33 is particularly attractive since other bromodomain modules (e.g., BRD4) have proven to be amenable to direct chemical inhibition ([@bib29]). However, we observe a modest expansion of myeloid cells upon short durations of TRIM33 suppression in vivo and *Trim33*^−/−^ mice have been shown to develop chronic myelomonocytic leukemia ([@bib3]). Thus, long-term inhibition of TRIM33 might have pro-tumorigenic effects in certain tissues. Nonetheless, our findings justify consideration of TRIM33-inhibition as a therapeutic approach in B cell neoplasms, which would be expected to unleash an apoptosis-promoting enhancer element.

Materials and methods {#s4}
=====================

Plasmids {#s4-1}
--------

For competition-based assays in murine cells, the LMN-GFP or LMN-mCherry shRNA retroviral vector were used (MSCV-miR30-shRNA-PGKp-NeoR-IRES-GFP/mCherry). When drug selection was required, some experiments were performed using MLP-GFP (MSCV-miR30-shRNA-PGKp-PuroR-IRES-GFP). For Annexin V experiments, the MLS vector was used (MSCV-miR30-shRNA-SV40p-GFP) to obtain a higher infection efficiency. For competition assays in human cell lines, the MLS-E vector was used (MSCV-miRE-shRNA-SV40p-GFP) ([@bib17]). All of the cloning procedures were performed using the In-Fusion cloning system (\#638909; Clontech, Mountain View, CA).

Cell culture and virus production {#s4-2}
---------------------------------

Murine B-ALL (driven by BCR-ABL and p19^Arf^ inactivation) ([@bib42]) and 38B9 ([@bib2]) were cultured in RPMI supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 0.055 mM 2-Mercaptoethanol. Derivation of MLL-AF9/Nras^G12D^ AML cells is described in [@bib46]. The T-ALL cell line was provided by I Aifantis (NYU) and was derived from TAL transgenic/HEB heterozygous mice with an acquired truncation of Notch1. Murine AML and T-ALL cells and human REH, SU-DHL, MM1S, and JURKAT cell lines were cultured in RPMI/10% FBS/1% penicillin/streptomycin.

The retroviral and lentiviral packaging cells Ecotropic Plat-E cells ([@bib27]) and HEK293T cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. All retroviral packaging was performed according to established protocols ([@bib27]). Virus was collected 48--72 hr post-transfection.

Negative selection RNAi screen {#s4-3}
------------------------------

A previously described LMN shRNA library targeting chromatin regulatory proteins was used ([@bib47]). Additional shRNAs were included in the library to allow comprehensive targeting of all bromodomain-containing proteins. shRNA plasmids from this library were arrayed individually in 96 well plates at 50 ng/µl for retrovirus preparation using Ecotropic Plat-E cells as described ([@bib27]). Viral transduction of B-ALL cells was also performed in 96 well plates, followed by flow-cytometry-based measurement of GFP positivity using a Guava Easycyte instrument (Millipore, Billerica, MA). Measurements were performed on day 2 and day 12 post-transduction. Renilla and Rpa3 control shRNAs were included with each 96 well plate as negative and positive controls, respectively. If an shRNA was introduced into B-ALL cells with a day 2 GFP percentage below 5%, this sample was discarded from the screen. The lower limit on GFP% measurements on day 12 was arbitrarily set at 0.2%. A single instance of Renilla and Rpa3 control shRNAs are included in the screen histogram shown in [Figure 1A](#fig1){ref-type="fig"}. The screen data can be found in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

Competition assay to measure cellular effects of shRNA {#s4-4}
------------------------------------------------------

To evaluate the effect of shRNAs on murine cell proliferation (e.g., in [Figure 1A--E](#fig1){ref-type="fig"}), cultures were retrovirally transduced with the indicated LMN-GFP shRNA vectors, followed by measurement of the GFP percentages over a time course post-infection using a Guava Easycyte flow cytometer. For double shRNA competition-based assays (e.g., [Figures 3J, 4B](#fig3 fig4){ref-type="fig"}), cells were first transduced with MLP-GFP (Ren, Bim, or PU.1 shRNA) and then were selected with puromycin (1 μg/ml). Cells were subsequently transduced with LMN-mCherry (Ren or TRIM33 shRNAs) and double GFP/mCherry positivity was tracked using a BD LSR2 flow cytometer. For human competition assays in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, the MLS-E vector was used and GFP was tracked using a Guava Easycyte instrument. shRNA sequences can be found in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.

Annexin V staining for cell death analysis {#s4-5}
------------------------------------------

In order to quantify the cell death effect induced by Renilla or TRIM33 shRNAs, B-ALL cells were transduced at a high efficiency (\>95% GFP) using the MLS-GFP vector. After 3 days post-infection, cells were spun down, washed with PBS and resuspended in 1× binding buffer and incubated with APC Annexin V antibody (as described by manufacturer protocol, \#550475; BD Pharmingen, San Diego, CA) and DAPI, followed by BD LSRII flow cytometry analysis. GFP gating was not performed. The three independent TRIM33 shRNAs revealed similar results. The data analysis was performed using Flowjo software.

Transgenic animal studies {#s4-6}
-------------------------

All experimental mouse procedures were approved by the Cold Spring Harbor Animal Care and Use Committee. Renilla and TRIM33 shRNA targeted ES cells were derived by Mirimus (Cold Spring Harbor, NY) as described ([@bib28]; [@bib12]), using site-specific integration of the shRNA cassette into the *Col1a1* locus of KH2 ES cells ([@bib6]). 8--10 week old mice heterozygous for alleles of shRen.713 or shTRIM33 and homozygous for ROSA26-rtTA-M2 alleles were treated with dox drinking water (2 mg/ml doxycycline and 2% sucrose) and dox food (625 mg/kg) for 7 or 28 days. Fluorescent markers (eGFP for shRenilla and TurboGFP for shTRIM33) were indicators of shRNA-expressing cells following doxycycline treatment. The animal health and body weight were monitored during the time course of experiments. Primers used for genotyping can be found in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.

To measure the impact of TRIM33 knockdown on hematopoietic lineages, bone marrow and spleen tissues were harvested from 8--10 week old transgenic mice following the administration of dox for 7 or 28 days. A single cell suspension of harvested samples was treated with ACK buffer (150 mM NH~4~Cl, 10 mM KHCO~3~, 0.1 mM EDTA) to lyse the red blood cells. The sample was then stained with hematopoietic lineage marker antibodies (1:200) in FACS buffer (1× PBS with 5% FBS and 0.05% NaN~3~) for 30 min and then subjected to BD LSRII flow cytometry analysis. Gating was performed on live cells (FSC/SSC) and on GFP^+^ cells prior to quantifying marker positivity. The GFP percentage in total bone marrow was approximately 75% on dox for shRen and shTRIM33 mice. The GFP percentage in the total spleen was approximately 15% for shTRIM33 and shRen mice on dox. This heterogeneity in GFP expression in these different tissues requires GFP gating to accurately define hematopoietic phenotypes using flow cytometry. The data analysis was performed using Flowjo software.

To evaluate the reversibility of the TRIM33 knockdown phenotype in bone marrow B lymphoid cell, animals were placed on dox for 7 days and a second cohort was placed on dox for 7 days followed by removal of dox for 21 additional days. B220 and Cd19 marker staining was performed as described above, but the GFP marker was not gated upon since GFP expression is extinguished upon removing dox. This accounts for the weaker B cell phenotype in this 7 day dox treatment from the findings presented in [Figure 1I](#fig1){ref-type="fig"}, in which GFP gating was performed.

For immunohistochemistry analysis of TRIM33 expression, transgenic mice were maintained on dox for 28 days. Mouse tissues were fixed overnight in 10% neutral buffered formalin and then washed with PBS. Samples were then processed using Shandon Excelsior Tissue processor and embedded in paraffin, 6 micron sections were then mounted onto VWR Superfrost Plus slides.

Western blotting {#s4-7}
----------------

For western blotting, whole cell lysates were prepared by direct lysis using SDS-PAGE sample buffer and about 50,000 cell equivalents were loaded into each lane. Samples were then separated by SDS-PAGE electrophoresis and transferred to nitrocellulose for detection using antibodies. For western blotting of mouse tissues, samples were harvested and lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) using a dounce homogenizer, then briefly sonicated and incubated on ice for 15 min. Pellets were spun down and the supernatant was collected and quantified using a Bradford assay. 20 μg of protein were loaded into each gel lane.

Immunohistochemistry {#s4-8}
--------------------

Deparaffinization of samples was done with Xylene (2 × 10 min) followed by ethanol rehydration (100%-2 × 5 min, 95% and 75% 2 min each) and washed in distilled water. 3% Hydrogen Peroxide was used for blocking endogenous peroxidase, followed by another wash. Antigen retrieval was done with Citrate buffer in an Electric Pressure Cooker then washed in TBS. Samples were then blocked with 5%NHS, 1%BSA in TBS for 1 hr at room temperature and incubated with TRIM33 antibody (1:500/1:1000) overnight at 4°C. Followed by washing with TBS and incubated with Vector mp-7401 anti-rabbit secondary antibody for 30 min and then washed again. Slides were then incubated with Vector ImmPACT DAB, SK-4105 for 3 min and then rinsed in water. Counterstaining was performed with Hematoxylin and coverslipping was performed with Surgipath mounting medium prior to analysis.

Chromatin immunoprecipitation {#s4-9}
-----------------------------

Cells were crosslinked with 1% formaldehyde for 20 min at room temperature and then quenched with 0.125 M glycine. Samples were sonicated and incubated with 5 μg of antibody overnight and then precipitated using Protein A Dynabeads (cat \#10002Dl; Life Technologies, Grand Island, NY). For TRIM33/PU.1 ChIP in B-ALL, 50 million cells were used for each ChIP conditions with 5 μg antibody. For histone modification ChIP experiments in B-ALL, 20 million cells were used for each ChIP conditions with 2 μg antibody. For whole spleen ChIP, 6--8 week old mice were sacrificed and a suspension of 30 million splenocytes was prepared for ChIP with 5 μg antibody. ChIP-qPCR was performed on the reverse crosslinked DNA samples as previously described ([@bib38]). All of the results were quantified by qPCR using SYBR green (ABI, Grand Island, NY) on an ABI 7900HT. Each IP signal was quantified based on an input standard curve dilution series of the pre-immunoprecipitated genomic DNA (IP/Input) to normalize for the differences of total amount of cells subjected for ChIP and for the different amplification efficiencies of various primer sets.

RT-qPCR analysis {#s4-10}
----------------

Total RNA was extracted from cells using Trizol reagent according to the manufacturer\'s instructions. Upon isolating RNA, DNase I was treated to eliminate contaminating genomic DNA. For cDNA synthesis, Q-Script cDNA SuperMix (Quanta BioScience, Gaithersburg, MD) was used. All results were quantified by qPCR performed using SYBR green (ABI) on an ABI 7900HT using the delta Ct method using *Gapdh* as a control gene.

All ChIP and RT-qPCR primers used in this study can be found in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.

ChIP-seq and RNA-seq library preparation {#s4-11}
----------------------------------------

ChIP DNA was purified using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) and ChIP-Seq libraries were constructed using TruSeq ChIP Sample Prep Kit (Illumina) following the manufacturer\'s instructions. The quality of each library was determined by Bioanalyzer analysis using the High Sensitivity chip (Agilent). Two independent biological replicates were performed for each ChIP-seq experiment. Barcoded libraries were sequenced in a multiplexed fashion with two to six libraries at equal molar ratio, with single end reads of 50 bases. For RNA-seq, total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA). Libraries were constructed using the TruSeq sample Prep Kit V2 (Illumina, San Diego, CA) according to the manufacturer\'s instructions. DNA libraries were sequenced using an Illumina HiSeq 2000 platform.

RNA-seq analysis {#s4-12}
----------------

The obtained reads were trimmed into 28 base reads corresponding to 9th to 36th position from the 5′ ends of the reads. These reads were mapped to the mouse genome (mm9) using Tophat software allowing no mismatch, then differentially expressed genes were analyzed by using Cuffdiff software. During this step, structural RNAs (e.g., ribosomal or mitochondrial RNA) were masked. To calculate relative fold change to control, only genes with expression cutoff above 5 reads per million per kilobase (RPKM) and OK test status were considered. Average RPKM from two biological replicates of each control (Ren) and TRIM33 shRNA expressed samples was then used to calculate fold change with log2 scale.

ChIP-seq analysis {#s4-13}
-----------------

The sequence reads were of 36 or 50 bp in length and mapped to the reference murine genome assembly NCBI37/mm9 using Bowtie. Alignments were performed using the following criteria: -m1, -v2. To identify ChIP-Seq peaks, we used the MACS version 1.4.0 beta (Model based Analysis of ChIP-Seq) peak finding algorithm by using a p value threshold of enrichment of 1e-5 as a cut-off. For AML, 38B9, and T-ALL, we also implemented a 10-fold IP/Input enrichment ratio as a filtering criteria. To identify reproducibly enriched regions of TRIM33 ChIP-Seq from two biological replicates, called peaks from MACS were compared and intersected. If the peaks showed at least 1 bp overlap between replicates, they were considered as reproducible. To calculate average tag counts from reproducible peaks, tag counts were normalized to total mapped reads, and further ranked by tag counts.

All ChIP-seq and RNA-seq data from this study can be found at the GEO accession super-series GSE66234.

FIMO/MEME motif analysis {#s4-14}
------------------------

Sequence coordinates from TRIM33 peak calling using MACS were used to obtain sequences of Bim-117 and Atp1b3 regions. Analysis was performed at the FIMO/MEME website: <http://meme.nbcr.net/meme/tools/fimo> using a p-value output threshold of 1E-4 and motif file JASPAR_CORE_2014_VERTEBRATES.MEME from the Jaspar database ([@bib26]).

For the unbiased discovery of motifs at TRIM33 enriched regions, 400 bp core sequences centered around reproducible TRIM33 peaks were submitted to the browser-based MEME-ChIP analysis (<http://meme.nbcr.net/meme/tools/meme-chip>).

CRISPR-Cas9 targeted deletion of *Bim* --117 {#s4-15}
--------------------------------------------

The MSCV-hCas9-PGK-Puro construct was derived by cloning the N terminal 3× FLAG tag human-codon optimized Cas9 cDNA (\#49535; Addgene) into the MSCV-PGK-Puro vector (\#634401; Clontech). The U6-sgRNA-EFS-mCherry vector was constructed using the lentiviral backbone from lentiCRISPR (\#49535; Addgene). All sgRNAs were designed using <http://crispr.mit.edu/> and cloned into the U6-sgRNA-EFS-mCherry vector following published protocols ([@bib32]). For sgRNA lentivirus production, HEK293T cells were transfected with sgRNA:pVSVg:psPAX2 plasmids in a 4:2:3 ratio by using PEI reagent (\#23966; Polysciences, Warrington, PA) following standard procedures. To generate CRISPR competent line, parental B-ALL and 38B9 cells were transduced with MSCV-hCas9-PGK-Puro construct followed by puromycin selection (1 μg/ml). To generate lines with a homozygous deletion of *Bim* --117, two sgRNAs were designed to target flanking sequences of the −117 element and were retrovirally co-transduced into B-ALL or 38B9 cells, followed by isolation of clonal lines by limiting dilution. Genomic DNA was prepared from each clone using QiAamp DNA mini kit (\#51304; Qiagen) following the manufacturer\'s instructions, followed by PCR-based screening for clones harboring a homozygous deletion, using primers that span the *Bim* enhancer region. The −117 deletion of individual clones was further verified by Sanger sequencing. sgRNA and genotyping primer sequences can be found in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.

Antibodies {#s4-16}
----------

Anti-TRIM33 antibody (A301-060A; Bethyl Laboratories, Montgomery, TX), Anti-PU.1 antibody (\#2266; Cell Signaling, Beverly, MA or sc-352; Santa Cruz, Dallas, TX), Anti-Bim antibody (\#2819; Cell Signaling), Anti-H3K27ac antibody (ab4729; Abcam, Cambridge, MA), Anti-H3K4me3 antibody (07-473; Millipore), Anti-ß-actin HRP antibody (\#A3854; Sigma, Ronkonkoma, NY), APC anti-mouse B220 (\#103212; BioLegend, San Diego, CA), APC anti-mouse CD-19, APC anti-mouse Mac-1/Cd11b (\#101211; BioLegend), APC anti-mouse Ly-6G/Gr-1 (\#17-5931; eBioscience, San Diego, CA), APC anti-mouse TER-119 (\#116212; BioLegend), APC anti-mouse CD-3 (\#100209; BioLegend).
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Howard Hughes Medical Institute, University of Colorado

,

United States

eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Trim33 prevents apoptosis in B lymphoblastic leukemia by decommissioning a single enhancer" for consideration at *eLife*. Your article has been favorably evaluated by Charles Sawyers (Senior editor) and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission:

The manuscript by Wang et al. describes a lineage-specific epigenetic dependency, namely on Trim33. Many B-lineage cancers and autoimmune diseases continue to be urgent clinical problems, increasing the impact of this manuscript. The authors define a novel mechanism, where highly clustered binding sites for the transcription factor PU.1 at enhancer sites are counteracted by Trim33. This disproportionally affects 2 genes including the apoptosis inducer *Bim*. The authors demonstrate functional importance of *Bim* and functional importance of a single enhancer element upstream of *Bim*. Thus, virtually all of the oncogenic effects of TRIM33 can be attributed to binding to a single site in the genome, a remarkable discovery.

The reviewers agreed that the paper was very interesting and well crafted, but there was some discussion about limited impact due to the fact that most mechanistic work was done in a single cell line, and that the mechanism of action of TRIM33 is largely unexplored. The reviewers agreed that further insight into the mechanism of action was not needed for a Short Report, but there was consensus on requiring validation of key mechanistic experiments in a second cell line.

More specifically, the authors show a unique higher density of PU.1 at the *Bim*-117 enhancer and antagonism of PU.1 by TRIM33 recruitment to this enhancer in B-cell derived leukemic and progenitor cell lines. However, while they show the initial phenotype for several B cell lines, B-ALL, 38B9 ([Figure 1B, 1C](#fig1){ref-type="fig"}) and other B cell cancer lines ([Figure 1--figure supplements 1B, 1C, 1D](#fig1s1){ref-type="fig"}), all mechanistic work (except for TRIM33 occupancy) is done in only one cell line (B-ALL). The authors should reproduce their mechanistic studies in a second cell line (e.g., 38B9). Otherwise the novelty of this work is somewhat limited: it is known that PU.1 binds enhancers, and that TRIM33 interacts with PU.1. The reviewers agreed on the need to delineate the PU.1/TRIM33/*BIM* pathway in 38B9 cells, with the exception of removal of the enhancer at the *BIM* locus, which was thought to be too involved and would delay publication.

Minor points:

1\) In the Discussion the authors claim TRIM33 as a therapeutic target "... since the major phenotypic abnormality in mice experiencing systemic Trim33 inhibition is a selective and reversible B lymphocyte deficiency." The authors do not address the other hematopoietic lineage phenotypes previously described by Aucagne et al., J. Clin. Invest., 2011 and Bai et al., Dev. Biol., 2013, most importantly the CMML phenotype. That is surprising as the authors also see an expansion of the granulocytic compartment after 1 week (BM, [Figure 1I](#fig1){ref-type="fig"}), and more dramatically 4 weeks (spleen, [Figure 1J](#fig1){ref-type="fig"}). Please discuss this.

2\) If PU.1 is a lineage-specific factor for many myeloid lineages, why would TRIM33 antagonize PU.1 specifically in B (progenitor) cells? What about PU.1 density at the *Bim* enhancers in AML or T-ALL cell lines (the authors only show TRIM33 occupancy in those)? One would expect that either PU.1 density is low or that *Bim* does not play a key role in these cell lines. This should be discussed.

3\) How do the authors imagine the interplay of TRIM33 and PU.1 in normal B cell differentiation? Is this mechanism active in vivo? The authors show that in the mouse model depleted for Trim33 B-lymphoid cells are selectively lost. They do not address whether apoptosis in the model is due to PU.1-TRIM33 antagonism. In fact, they show that TRIM33 binds to the *Bim* enhancer in normal spleen. However, work by Oliver et al., J. Exp. Med., 2004 shows that *Bim* is expressed in B-cell precursors. Is this also true in the authors' system? If so, how do they explain *Bim* expression despite TRIM33 occupancy at the enhancer? What are the absolute *Bim* levels compared to those in the B-ALL model?

4\) The fact the GFP-gated cells in vivo show more efficient B-lineage depletion than non-GFP-gated cells (and that there are non-GFP cells present under induced conditions in the marrow) suggests to me that the mouse strain with inducible shRNA/GFP has variegated expression in the B-linage or even whole BM (position effect). I believe this does not affect the manuscript\'s message, but the authors should clarify.

5\) The authors allude to other factors with documented peak number: MyoD ∼39,000 and Pax5 ∼20,000 sites ([@bib9]; [@bib33]). In a side by side comparison, using the same peakfinder and same parameters including p-value cutoff, how many significant peaks are there for Trim33 in the p190-leukemia cells? It might be that not the number of peaks is different from characterized transcriptional regulators but the existence of the unusual outliers including *Bim*. Please clarify.
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Author response

*The reviewers agreed that the paper was very interesting and well crafted, but there was some discussion about limited impact due to the fact that most mechanistic work was done in a single cell line, and that the mechanism of action of TRIM33 is largely unexplored. The reviewers agreed that further insight into the mechanism of action was not needed for a Short Report, but there was consensus on requiring validation of key mechanistic experiments in a second cell line*.

*More specifically, the authors show a unique higher density of PU.1 at the Bim-117 enhancer and antagonism of PU.1 by TRIM33 recruitment to this enhancer in B-cell derived leukemic and progenitor cell lines. However, while they show the initial phenotype for several B cell lines, B-ALL, 38B9 (*[*Figure 1B, 1C*](#fig1){ref-type="fig"}*) and other B cell cancer lines (*[*Figure 1--figure supplements 1B, 1C, 1D*](#fig1s1){ref-type="fig"}*), all mechanistic work (except for TRIM33 occupancy) is done in only one cell line (B-ALL). The authors should reproduce their mechanistic studies in a second cell line (e.g., 38B9). Otherwise the novelty of this work is somewhat limited: it is known that PU.1 binds enhancers, and that TRIM33 interacts with PU.1. The reviewers agreed on the need to delineate the PU.1/TRIM33/*BIM *pathway in 38B9 cells, with the exception of removal of the enhancer at the* BIM *locus, which was thought to be too involved and would delay publication*.

Our revised manuscript now includes several additional mechanistic experiments evaluating the PU.1/TRIM33/*BIM* pathway in 38B9 cells, which includes ChIP-seq analysis of TRIM33 in 38B9 ([Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). This epigenomic analysis highlights a similar binding pattern for TRIM33 at the *Bim* locus in this cell type. We find a larger number of peaks for TRIM33 in 38B9, however, *Bim*-117 and Atp1b3-35 are among the most profoundly enriched in 38B9, similar to the observations in B-ALL ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}). We also show by ChIP-qPCR that PU.1 occupies the *Bim*-117 and Atp1b3-35 regions in 38B9, much like it does in B-ALL ([Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}). We have also performed experiments in which we knock down *Bim* and PU.1 in 38B9, which we shows alleviates the TRIM33 requirement, in agreement with the observation in B-ALL ([Figure 3--figure supplement 4](#fig3s4){ref-type="fig"} and [Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}). Finally, we have also performed a CRISPR-based deletion of the *Bim*-117 element in 38B9, and found that this bypasses the TRIM33 requirement in this cell type ([Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}).

Collectively, these findings provide strong support that the PU.1/TRIM33/*BIM* pathway is relevant in both 38B9 and B-ALL cell lines. In addition, we now have two independent cell lines in which we can show that TRIM33 performs an essential function through a single *cis* element.

*Minor points*:

*1) In the Discussion the authors claim TRIM33 as a therapeutic target "... since the major phenotypic abnormality in mice experiencing systemic Trim33 inhibition is a selective and reversible B lymphocyte deficiency." The authors do not address the other hematopoietic lineage phenotypes previously described by Aucagne et al., J. Clin. Invest., 2011 and Bai et al., Dev. Biol., 2013, most importantly the CMML phenotype. That is surprising as the authors also see an expansion of the granulocytic compartment after 1 week (BM,* [*Figure 1I*](#fig1){ref-type="fig"}*), and more dramatically 4 weeks (spleen,* [*Figure 1J*](#fig1){ref-type="fig"}*). Please discuss this*.

In our revised manuscript, we now discuss the potential for tumorigenic effects incurred by TRIM33 inhibition in certain tissues, in light of the Aucagne et al. study showing CMML-like disease in TRIM33-ko mice. This appears in the last paragraph of the Discussion section.

*2) If PU.1 is a lineage-specific factor for many myeloid lineages, why would TRIM33 antagonize PU.1 specifically in B (progenitor) cells? What about PU.1 density at the* Bim *enhancers in AML or T-ALL cell lines (the authors only show TRIM33 occupancy in those)? One would expect that either PU.1 density is low or that* Bim *does not play a key role in these cell lines. This should be discussed*.

This is an important issue, which was not adequately addressed or discussed in the original manuscript. To carefully define the cell type-specific pattern of TRIM33 occupancy in these different leukemia contexts, we have now performed ChIP-seq analysis of TRIM33 in 38B9, AML, and T-ALL cell lines. This analysis shows that TRIM33 occupies the *Bim*-117 and *Atp1b3*-35 enhancers in B-ALL, 38B9, and AML, but not in T-ALL ([Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). Furthermore, we show that occupancy of TRIM33 at *Bim* and *Atp1b3* occurs at extremely high levels in 38B9 and AML as compared to other genomic sites, which resembles the skewed pattern observed in B-ALL ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}). We have also performed ChIP-qPCR analysis of PU.1 in 38B9, AML, and T-ALL cell lines ([Figure 2--figure supplement 2](#fig2s2){ref-type="fig"}). This reveals PU.1 occupying *Bim*-117 and Atp1b3-35 in 38B9 and AML, but not T-ALL. Hence, these findings reveal that PU.1 and TRIM33 occupy similar elements at the *Bim* and Atp1b3 loci in B-lymphoid and myeloid leukemias, but not in T-lymphoid cells.

The ChIP-seq observation of TRIM33 occupancy at the *Bim*-117 enhancer in AML was unexpected, as our original manuscript included ChIP-qPCR data showing a lack of TRIM33 occupancy at this region in AML. This discrepancy prompted us to perform additional TRIM33 and PU.1 ChIP-qPCR experiments in 3 additional early passage AML cultures, which were all derived independently from the MLL-AF9/Nras^G12D^ mouse model. The results are shown below and validate the ChIP-seq findings that TRIM33 occupies the *Bim*-117 region in AML ([Author response image 1](#fig5){ref-type="fig"}). We do not fully understand why our original results were erroneous with regard to TRIM33 occupancy in AML, but this may due to the use of a late-passage of AML cell lines for this experiment in the original submission, whereas the ChIP-seq and new ChIP-qPCR experiments was performed in early passage AML cultures. Alternatively, it is possible there was cell culture mixup that led to this incorrect conclusion. We apologize for this error in the original submission, which we have corrected in the revised manuscript.

These findings now raise the issue as to why *Bim* expression and apoptosis are unaffected in AML cells upon TRIM33 knockdown, despite PU.1/TRIM33 occupancy at *Bim* -117 in this cell type. An analysis of H3K27ac in B-ALL and AML reveals a significant difference in the *Bim* enhancer landscape in these two cell types. In B-ALL, the -117 kb region is among the most hyperacetylated regions in the vicinity of *Bim*, suggesting this enhancer is among the most active at the *Bim* locus in this cell type. In AML we observe a unique enhancer cluster at ∼66 kb upstream of *Bim* which is not observed in B-ALL ([Figure 4--figure supplement 2](#fig4s2){ref-type="fig"}). Notably, the levels of H3K27ac at this region are substantially higher than the level of H3K27ac at the -117 kb region. This raises the possibility that a different set of enhancers control *Bim* in AML, whose strength might be substantially greater than the activity of the -117 region. This leads us to speculate that, while TRIM33 and PU1 occupy the *Bim* locus in AML, this element is not a major contributor to *Bim* expression in this cell type, which is instead regulated by the -66 enhancer cluster. We provide a new [Figure 4--figure supplement 2](#fig4s2){ref-type="fig"} and a new paragraph discussing this point in the revised manuscript (last paragraph of the Results section).10.7554/eLife.06377.023Author response image 1.ChIP-qPCR of TRIM33 and PU.1 in 3 independent MLL-AF9/Nras^G12D^ acute myeloid leukemia cell lines, which are all early passage cultures derived from leukemic mice.**DOI:** [http://dx.doi.org/10.7554/eLife.06377.023](10.7554/eLife.06377.023)

*3) How do the authors imagine the interplay of TRIM33 and PU.1 in normal B cell differentiation? Is this mechanism active in vivo? The authors show that in the mouse model depleted for Trim33 B-lymphoid cells are selectively lost. They do not address whether apoptosis in the model is due to PU.1-TRIM33 antagonism. In fact, they show that TRIM33 binds to the* Bim *enhancer in normal spleen. However, work by Oliver et al., J. Exp. Med., 2004 shows that* Bim *is expressed in B-cell precursors. Is this also true in the authors' system? If so, how do they explain* Bim *expression despite TRIM33 occupancy at the enhancer? What are the absolute* Bim *levels compared to those in the B-ALL model?*

Our manuscript does not completely address whether the TRIM33/PU.1 antagonism is operating during normal B cell development. However, there are several lines of suggestive evidence that point to the observations in B-ALL being relevant during normal B cell differentiation. First, we observe a similar sensitivity in normal and transformed B cells to TRIM33 knockdown. Second, we observe PU.1 binding to the *Bim*-117 and *Atp1b3*-35 regions in previously published ChIP-seq datasets obtained from normal B cell progenitors (Heinz and Glass, Molecular Cell 2010, PMID: 20513432). Third, we observe TRIM33 occupancy at the *Bim*-117 and *Atp1b3*-35 regions in whole spleen. All of these findings would be consistent with TRIM33/PU.1 antagonism being relevant to the phenotype observed in TRIM33-deficient mice, however definitive evidence will require additional genetic experiments in normal B lymphoid cells. We describe the potential relevance of TRIM33 for regulating normal B cell development in the Discussion section.

It should be noted that *Bim* is actually expressed at reasonably high levels in B-ALL cells even in the presence of TRIM33 (RPKM value of 12.6 from B-ALL RNA-seq). It can also be appreciated in [Figure 2C](#fig2){ref-type="fig"} that the *Bim* promoter exhibits robust H3K4me3 in B-ALL despite TRIM33 occupancy at the -117 region. In addition, by Western blotting we can readily detect *Bim* protein in TRIM33-proficient B-ALL cells ([Figure 4A](#fig4){ref-type="fig"}). The *Bim* locus in B-ALL cells also harbors multiple H3K27ac peaks, suggesting multiple active enhancers are contributing to *Bim* expression, with TRIM33 only antagonizing one of these elements. Hence, our findings are consistent with Oliver et al., 2004, in that *Bim* is expressed in these different normal and malignant B cells, but this expression is just below the critical threshold for committing cells to undergo apoptosis. Hence, targeting TRIM33 tips this balance by quantitatively increasing *Bim* expression through releasing the activity of one enhancer. It does not appear that TRIM33 regulates an on/off switch of *Bim* expression. For space considerations of a short report, we have not provided an extensive description of this issue in the text of the manuscript.

*4) The fact the GFP-gated cells in vivo show more efficient B-lineage depletion than non-GFP-gated cells (and that there are non-GFP cells present under induced conditions in the marrow) suggests to me that the mouse strain with inducible shRNA/GFP has variegated expression in the B-linage or even whole BM (position effect). I believe this does not affect the manuscript\'s message, but the authors should clarify*.

In the subsection headed "Transgenic animal studies" of the Methods section, we describe in greater detail the GFP percentages in the bone marrow and spleen following dox administration and the variegated expression pattern of shRNA/GFP in these animals. The bone marrow is approximately 75% GFP+ and the spleen is approximately 15% GFP+, which highlights the need for GFP gating to accurately measure effects on normal hematopoietic cells.

*5) The authors allude to other factors with documented peak number: MyoD ∼39,000 and Pax5 ∼20,000 sites (*[@bib9]*;* [@bib33]*). In a side by side comparison, using the same peakfinder and same parameters including p-value cutoff, how many significant peaks are there for Trim33 in the p190-leukemia cells? It might be that not the number of peaks is different from characterized transcriptional regulators but the existence of the unusual outliers including* Bim*. Please clarify*.

The Pax5 study used the same algorithm (MACS) as we have used to characterize TRIM33 occupancy. In fact, in the Pax5 ChIP-seq analysis the authors used an even greater stringency of cutoffs than we have used when we defined 31 TRIM33 peaks in B-ALL. Hence, applying the same cutoffs to the TRIM33 ChIP-seq data would have revealed even fewer peaks than the 31 we were able to identify. As described below, the absolute number of peaks identified using ChIP-seq must caveated by the arbitrary enrichment cutoffs used to define occupancy.

Our revised manuscript now includes TRIM33 ChIP-seq performed in 38B9, AML, and T-ALL. This analysis reveals a substantially greater number of peaks overall in each of these cell types that achieves statistical significance using standard MACS peak calling criteria. However, we note in each dataset that there are indeed, as the reviewers suggest, the presence of unusual outliers with exceptional occupancy, such as *Bim* and Atp1b3. Throughout the text of the revised manuscript, we have more clearly described this type of pattern. For instance, we have removed the description of TRIM33 occupancy as 'sparse' in the B-ALL genome (which was the wording in the original Abstract), since we should not over-interpret the absolute number of peaks identified in the ChIP-seq experiments. Instead, it is more appropriate to describe the disproportionate accumulation of TRIM33 at a small number of sites in each cell type, which appears to be a consistent pattern in B-ALL, 38B9, and AML, but to a lesser extent in T-ALL. Our revised manuscript also includes a MEME-based motif analysis of the TRIM33 peaks in each of these cell types, which confirms the relevance of PU.1 in myeloid and B lymphoid cell types, but reveals additional TFs as contributing the TRIM33 recruitment in T-ALL ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}).

[^1]: The Thomas N Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, Kyoto, Japan.
